Navigation Links
Researchers identify proteins in lung cancer cells that may provide potential drug targets

(Boston) Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy. In addition, the BU researchers have developed a new computational strategy to analyze this data and specifically identify key biological pathways (molecular circuits) that are active in cancer and "dormant" in normal cells. The study which appears in the November 25th issue of PLoS ONE, will ultimately lead to the development of drugs specifically aimed to inhibit these proteins.

According to the BU researchers, there are many features that make cancer cells different from normal cells. They look different histologically, they proliferate and divide at different rates, they are immortal unlike normal cells, and are less communicative with their neighbor cells. They are also more "selfish" in refusing to commit suicide (programmed cell death) which normal cells do when their genomes become unstable.

Much of the cellular machinery involved with these biological processes is controlled by a command control and communication system called signal transduction. Signal transduction is in large part controlled by a process called phosphorylation. When a protein is phosphorylated it either becomes active or repressed depending on its special function. "Therefore, identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said co-senior author Simon Kasif, PhD, who is the co-director of the Center of Advanced Genomic Technology and a professor in the department of biomedical engineering at BU. "Drugs are most effective on cancers when they attack the proteins that are activated," he added.

While cancers are highly heterogeous in their make-up, the BU researchers believe that a drug that would target this collection of proteins would be effective treatment for most lung cancers.

"This is the first statistically validated phosphopeptide signature to diagnose any disease, much less cancer or lung cancer," explained senior co-author Martin Steffen, MD, PhD, an assistant professor of pathology and laboratory medicine at BUSM, and director, Proteomics Core Facility at BUSM.


Contact: Gina DiGravio
Boston University Medical Center

Related medicine news :

1. Researchers Identify Possible Causative Mutation for Crohn's Disease: Crohn's & Colitis Foundation Annual Conference to Present Emerging Research
2. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
3. Researchers identify role of gene in tumor development, growth and progression
4. On the trail of a vaccine for Lyme disease: Yale researchers target tick saliva
5. UCLA researchers create fly paper to capture circulating cancer cells
6. Researchers focus on helping dying patients take care of unfinished business
7. Mount Sinai researchers to test first gene therapy For Alzheimers patients
8. Wistar researchers show targeting normal cells in tumors slows growth
9. K-State researchers studying link between climate change and cattle nutritional stress
10. Cornell Researchers Identify a Weak Link in Cancer Cell Armor
11. Researchers notch a victory toward new kind of cancer drug
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... 25, 2015 , ... Dental professionals who would like to become more proficient ... attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held ... the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... athletic programs, launches new Wimbledon Athletics Facebook page to educate the ... for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 die ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Research ... of the "Membranes Market - Global Forecast to ... Asia-Pacific , accounting for 37.21% of the ... Asia-Pacific region is projected to ... This growth has been attributed primarily to the fast ...
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... shareholders held today, the Company,s shareholders voted in favor ... announced agreement and plan of merger (the "Merger Agreement") ...
Breaking Medicine Technology: